3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Carcinoma, Hepatocellular
4
Uterine Cervical Neoplasms
3
Prostatic Neoplasms
3
Uterine Cervical Dysplasia
2
Thyroid Nodule
2
Sarcoma
2
Papillomavirus Infections
2
Melanoma
2
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Spinal Cord Compression
1
Recurrence
1
Prostatic Hyperplasia
1
Precancerous Conditions
1
Pancreatic Ductal Adenocarcinoma
1
Neoplasms, Unknown Primary
1
Neoplasms by Site
1
Neoplasms
1
Liver Neoplasms
1
Hyperthyroidism
1
HIV Infections
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Gastrointestinal Neoplasms
1
Interventions
pembrolizumab
5
padeliporfin
5
Nivolumab
5
fludarabine
4
aldesleukin
4
Ipilimumab
4
Cyclophosphamide
4
atezolizumab
3
Specimen Handling
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Carboplatin
3
vedolizumab
2
olaparib
2
niraparib
2
motexafin gadolinium
2
cabozantinib
2
anlotinib
2
abiraterone
2
Therapeutics
2
Sunitinib
2
Standard of Care
2
Riluzole
2
Radiation Dose Hypofractionation
2
Prednisone
2
Pluvicto
2
Mitomycin
2
LDP-02
2
Infliximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urogenital Neoplasms
×
Transurethral Resection of Prostate
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled